Sofinnova details Abivax (NASDAQ: ABVX) stake and $90M royalty buyback

Rhea-AI Filing Summary

Sofinnova-affiliated investors have updated their stake in Abivax S.A. following a royalty buyback deal. As of May 11, 2026, Sofinnova Crossover I SLP directly holds 3,377,494 Ordinary Shares, representing about 4.3% of Abivax’s outstanding Ordinary Shares and 5,499,478 voting rights, or about 6.7% of voting rights.

On May 4, 2026, Abivax repurchased royalty certificates from Sofinnova and other holders for an aggregate $90.0 million, split between $45.0 million in cash and $45.0 million in shares through the issuance of 403,347 Ordinary Shares in a private placement. Sofinnova Crossover I SLP received 42,755 ADSs in this transaction, and Abivax agreed to register these ADSs for resale. The filing also notes that Kinam Hong is no longer on Abivax’s Board of Directors.

Insights

Equity ownership & transactions analyst

Sofinnova discloses a royalty buyback-paid partly in equity and updates its Abivax stake.

The filing shows Sofinnova Crossover I SLP holding 3,377,494 Ordinary Shares of Abivax, equal to about 4.3% of shares and 5,499,478 voting rights, or 6.7% of voting rights, based on Abivax’s stated outstanding totals.

Abivax repurchased royalty certificates for $90.0 million, split evenly between cash and new equity via 403,347 Ordinary Shares in a private placement, of which Sofinnova received 42,755 ADSs. This converts a royalty obligation into a mix of cash outlay and share issuance.

The issuer registered the ADSs for resale, giving Sofinnova flexibility to sell, while the filing stresses current investment intent and the possibility of future purchases or sales. The document also notes governance change as Kinam Hong steps off the board, reducing direct influence over Abivax’s corporate decisions.

Key Figures

Royalty buyback value: $90.0 million Cash portion of buyback: $45.0 million Share portion of buyback: $45.0 million in 403,347 shares +5 more

8 metrics

Royalty buyback value $90.0 million Aggregate consideration to repurchase royalty certificates on May 4, 2026

Cash portion of buyback $45.0 million Cash paid by Abivax to repurchase royalty certificates

Share portion of buyback $45.0 million in 403,347 shares Value and amount of Ordinary Shares issued in private placement

ADSs received by Sofinnova 42,755 ADSs ADSs issued to Sofinnova Crossover I SLP in the private placement

Ordinary Shares held 3,377,494 Ordinary Shares Shares directly held by Sofinnova Crossover I SLP as of May 11, 2026

Voting rights held 5,499,478 voting rights Abivax voting rights attributed to the reporting persons, about 6.7% of total

Shares outstanding 79,694,535 Ordinary Shares Abivax Ordinary Shares outstanding as of March 31, 2026, adjusted for placement

Voting rights outstanding 82,047,884 voting rights Abivax voting rights outstanding as of March 31, 2026, adjusted for placement

Key Terms

American depositary shares, royalty certificates, Purchase Agreement, private placement, +2 more

6 terms

American depositary shares financial

"including ordinary shares represented by American depositary shares ("ADS")"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

royalty certificates financial

"repurchase royalty certificates issued to SC, and the other shareholders, on September 7, 2022"

Royalty certificates are tradable claims that give the holder a right to a portion of future payments tied to an asset’s revenue—such as a patent, drug sales, mineral production, or a licensing deal. For investors they act like buying a steady slice of a future cashflow stream: returns depend on how well the underlying asset performs, offering potential income and diversification but also exposure to the asset’s commercial risk.

Purchase Agreement financial

"The 42,755 ADSs were acquired in exchange for royalty certificates held by SC pursuant to the Purchase Agreement"

A purchase agreement is a legally binding contract that spells out exactly what is being bought, for how much, and under what conditions, including timelines, seller and buyer promises, and protections if things go wrong. For investors it matters because the agreement fixes the deal’s price, risks and closing conditions—like a detailed receipt and return policy for a large transaction—so it helps determine whether the deal will complete and how it will affect the company’s value and cash flow.

private placement financial

"through the issuance of 403,347 ordinary shares, including in the form of ADS in a private placement"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

voting rights financial

"has 5,499,478 voting rights related to such shares"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

beneficially owns financial

"The Reporting Person beneficially owns 3,377,494 Ordinary Shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Abivax S.A.

(Name of Issuer)

Ordinary Shares, par value EUR0.01 per share

(Title of Class of Securities)

00370M103

(CUSIP Number)

Armance Bordes
7-11, boulevard Haussmann,
Paris, I0, 75009
33 1 76 23 41 09

John Partigan Lloyd Spencer
Nixon Peabody LLP, 799 9 Street NW Ste 500
Washington, DC, 20001
202-585-8000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/07/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Sofinnova Crossover I SLP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note in relation to Items 7 and 8: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Crossover I SLP ("SC"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat"), the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,494 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Sofinnova Partners SAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note in relation to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,478 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Antoine Papiernik

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,494 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Cedric Moreau

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,494 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Kinam Hong

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,494 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,844 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Joseph Anderson

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,494 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Jacques Theurillat

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,499,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,377,494.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,499,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,377,494 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 5,499,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement (as defined below).

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value EUR0.01 per share
(b)	Name of Issuer: Abivax S.A.
(c)	Address of Issuer's Principal Executive Offices: 7-11, boulevard Haussmann, Paris, FRANCE , 75009.
Item 1 Comment: Introductory Statement: This Amendment No. 5 (this "Amendment"), being filed by Sofinnova Crossover I SLP ("SC"), Sofinnova Partners SAS, a French corporation ("SP SAS"), Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat") the members of the investment committee of SC (collectively, the "Listed Persons" and together with SC and SP SAS, the "Reporting Persons"), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on October 30, 2023, as amended by Amendment No. 1, filed with the SEC on February 14, 2025, as further amended by Amendment No. 2, filed with the SEC on July 31, 2025, as amended by Amendment No. 3, filed with the SEC on October 30, 2025, and as further amended by Amendment No. 4, filed with the SEC on January 14, 2026 (collectively, as amended, the "Schedule 13D"). This Schedule 13D relates to the Ordinary Shares, par value EUR0.01 per share (the "Ordinary Shares"), including ordinary shares represented by American Depositary Shares ("ADS"), of Abivax SA, a societe anonyme incorporated under the laws of the French Republic (the "Issuer"). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.
Item 2.	Identity and Background
(d)	During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3.	Source and Amount of Funds or Other Consideration
	The 42,755 ADSs were acquired in exchange for royalty certificates held by SC pursuant to the Purchase Agreement, dated May 4, 2026 (as further defined below).
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On May 4, 2026, SC, among various other shareholders, entered into a Purchase Agreement with the Issuer to repurchase royalty certificates issued to SC, and the other shareholders, on September 7, 2022. The Issuer repurchased the royalty certificates in full by paying an aggregate consideration of $90.0 million, $45.0 million of which was paid in cash and $45.0 million was paid in shares through the issuance of 403,347 ordinary shares, including in the form of ADS in a private placement (the "Private Placement"). In the Private Placement, SC received 42,755 ADSs. On May 7, 2026, the Issuer registered the offering and resale of the ADSs. In addition to the Private Placement, Mr. Hong no longer serves as a member of the Board of Directors of the Issuer and no longer has influence over the corporate activities of the Issuer. Mr. Hong is no longer entitled to receive cash attendance fees. All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D. However, as part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: As of May 11, 2026, SC held directly 3,377,494 Ordinary Shares representing approximately 4.3% of the Issuer's outstanding Ordinary Shares and 5,499,478 voting rights representing approximately 6.7% of the Issuer's outstanding voting rights. None of the other Reporting Persons hold any Ordinary Shares or ADSs directly. SP SAS is the management company of SC and may be deemed to have shared voting and investment control over the Ordinary Shares and ADSs held by SC. Each of Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson and Jacques Theurillat are the members of the investment committee of SC and may be deemed to have shared voting and investment control over the Ordinary Shares and ADSs held by SC. Each of such individuals disclaims beneficial ownership of such Ordinary Shares and ADSs except to the extent of their pecuniary interest therein. The ownership percentages are based upon 79,694,535 of the Issuer's Ordinary Shares outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement. The voting percentages are based upon 82,047,884 voting rights outstanding as of March 31, 2026, as adjusted to reflect the shares issued in the Private Placement.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except as disclosed herein, there have been no other reportable transactions with respect to the Ordinary Shares or ADSs of the Issuer within the last 60 days by the Reporting Persons.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	On May 4, 2026, SC entered into a Purchase Agreement with Issuer to repurchase royalty certificates issued to SC, among other shareholders, on September 7, 2022, in exchange for 42,755 ADSs. Pursuant to the Purchase Agreement, the Issuer agreed to register the new ADSs for resale. The description of the Purchase Agreement herein is not complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed herewith as Exhibit 99.2 and incorporated herein by reference. Kinam Hong, a member of the investment committee of SC, is no longer a member of the Issuer's Board of Directors.
Item 7.	Material to be Filed as Exhibits.
	EX 99.1 - Agreement regarding filing of joint Schedule 13D (incorporated by reference from Exhibit 99.1 to Schedule 13D filed by the Reporting Persons on October 30, 2023) EX 99.2 - Purchase Agreement, dated May 4, 2026, by and between the Issuer and the Selling Shareholders (listed therein) (incorporated by reference from Exhibit 10.1 to Form 6-K filed by the Issuer on May 7, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sofinnova Crossover I SLP

Signature:	/s/ Antoine Papiernik
Name/Title:	Managing Partner
Date:	05/11/2026

Sofinnova Partners SAS

Signature:	/s/ Antoine Papiernik
Name/Title:	Managing Partner
Date:	05/11/2026

Antoine Papiernik

Signature:	/s/ Antoine Papiernik
Name/Title:	Antoine Papiernik
Date:	05/11/2026

Cedric Moreau

Signature:	/s/ Cedric Moreau
Name/Title:	Cedric Moreau
Date:	05/11/2026

Kinam Hong

Signature:	/s/ Kinam Hong
Name/Title:	Kinam Hong
Date:	05/11/2026

Joseph Anderson

Signature:	/s/ Joseph Anderson
Name/Title:	Joseph Anderson
Date:	05/11/2026

Jacques Theurillat

Signature:	/s/ Jacques Theurillat
Name/Title:	Jacques Theurillat
Date:	05/11/2026

FAQ

How many Abivax (ABVX) shares does Sofinnova currently beneficially own?

Sofinnova Crossover I SLP beneficially owns 3,377,494 Abivax Ordinary Shares. These represent about 4.3% of Abivax’s 79,694,535 Ordinary Shares outstanding as of March 31, 2026, adjusted for the private placement described in the filing.

What percentage of Abivax (ABVX) voting rights is controlled by Sofinnova?

The reporting persons have 5,499,478 voting rights in Abivax, representing approximately 6.7% of the issuer’s 82,047,884 voting rights outstanding as of March 31, 2026, after adjusting for shares issued in the private placement transaction.

What is the value and structure of Abivax’s royalty certificate repurchase with Sofinnova?

Abivax repurchased royalty certificates from Sofinnova and other holders for an aggregate consideration of $90.0 million. The payment was split into $45.0 million in cash and $45.0 million in newly issued shares, including 403,347 Ordinary Shares in a private placement.

How many ADSs did Sofinnova receive in Abivax’s private placement?

In the private placement, Sofinnova Crossover I SLP received 42,755 American depositary shares (ADSs) of Abivax. These ADSs were issued as part of the $45.0 million share component of the royalty certificate repurchase consideration detailed in the filing.

Did Abivax register Sofinnova’s new ADSs for resale?

Yes. The filing states that on May 7, 2026, Abivax registered the offering and resale of the ADSs issued in the private placement. This registration allows the ADS holders, including Sofinnova, to resell these securities in compliance with applicable securities regulations.

What governance change involving Sofinnova’s representatives at Abivax is disclosed?

The document notes that Kinam Hong, a member of Sofinnova Crossover I SLP’s investment committee, no longer serves on Abivax’s Board of Directors. As a result, Hong no longer influences Abivax’s corporate activities or receives cash attendance fees from board service.